Language:

Differences in the HbA1c-lowering efficacy of glucagon-like peptide-1 analogues between Asians and non-Asians: a systematic review and meta-analysis

Diabetes, obesity & metabolism, 2014-10, Vol.16 (10), p.900-909

2014 John Wiley & Sons Ltd ;2014 John Wiley & Sons Ltd. ;ISSN: 1462-8902 ;EISSN: 1463-1326 ;DOI: 10.1111/dom.12293 ;PMID: 24655583 ;CODEN: DOMEF6

Full text available

Citations Cited by

Actions
1. Add to My Research
2. Remove from My Research
3. E-mail
4. Print
5. Permalink
6. Citation
7. EasyBib
8. EndNote
9. RefWorks
10. Delicious
11. Export RIS
12. Export BibTeX

Title:
Differences in the HbA1c-lowering efficacy of glucagon-like peptide-1 analogues between Asians and non-Asians: a systematic review and meta-analysis
Author: Kim, Y. G. ; Hahn, S. ; Oh, T. J. ; Park, K. S. ; Cho, Y. M.
Subjects: Asian ; Asian Continental Ancestry Group - statistics & numerical data ; Blood Glucose - drug effects ; BMI ; Body Weight - drug effects ; Confidence intervals ; Diabetes Mellitus, Type 2 - blood ; Diabetes Mellitus, Type 2 - drug therapy ; Dipeptidyl-Peptidase IV Inhibitors - therapeutic use ; GLP-1 ; Glucagon-Like Peptide 1 - analogs & derivatives ; Glucagon-Like Peptide 1 - therapeutic use ; Humans ; hypoglycaemia ; Liraglutide ; Medical research ; meta-analysis ; Peptides - therapeutic use ; Randomized Controlled Trials as Topic ; systematic review ; Treatment Outcome ; type 2 diabetes ; Venoms - therapeutic use
Is Part Of: Diabetes, obesity & metabolism, 2014-10, Vol.16 (10), p.900-909
Description: Aims To compare the HbA1c‐lowering efficacy of glucagon‐like peptide‐1 (GLP‐1) analogues between Asians and non‐Asians with type 2 diabetes. Methods We searched randomized controlled trials from MEDLINE, EMBASE, LILACS, CENTRAL and ClinicalTrials.gov. Studies described in English were included if the treatment duration was 12 weeks or more, information about ethnicity and baseline HbA1c values were available and a GLP‐1 analogue was compared with a placebo. For the ethnic comparison, we divided the studies into Asian‐dominant studies (≥50% Asian participants) and non‐Asian‐dominant studies (<50% Asian participants). Results Among the 837 searched studies, 15 trials were included for the meta‐analysis. The weighted mean difference of HbA1c with GLP‐1 analogues was −1.16% [95% confidence interval (CI) −1.48, −0.85] in the Asian‐dominant studies and −0.83% (95% CI −0.97, −0.70) in the non‐Asian‐dominant studies. The between‐group difference was −0.32% (95% CI −0.64, −0.01; p = 0.04). The relative risk (RR) with 95% CIs for achieving the target HbA1c ≤7.0% tended to be greater in the Asian‐dominant studies [RR 5.7 (3.8, 8.7)] than in the non‐Asian‐dominant studies [RR 2.8 (2.4, 3.3)]. Body weight changes were similar between the two groups. Hypoglycaemia tended to be more common in Asian‐dominant studies (RR 2.8 [2.3, 3.5]) than in non‐Asian‐dominant studies (RR 1.5 [1.2, 1.8]), but severe hypoglycaemia was very rare in both groups. Conclusion GLP‐1 analogues lower HbA1c more in Asian‐dominant studies than in non‐Asian‐dominant studies. Further studies are warranted to explore the potential mechanisms of the ethnic difference.
Publisher: Oxford, UK: Blackwell Publishing Ltd
Language: English
Identifier: ISSN: 1462-8902
EISSN: 1463-1326
DOI: 10.1111/dom.12293
PMID: 24655583
CODEN: DOMEF6
Source: MEDLINE
Alma/SFX Local Collection

Back to results list


INSPIRE LIBRARY - TON DUC THANG UNIVERSITY	(84-028) 37 755 057	Feedback
19 Nguyen Huu Tho St. Dist.7, HCM	thuvien@tdtu.edu.vn	Feedback

Differences in the HbA1c-lowering efficacy of glucagon-like peptide-1 analogues between Asians and non-Asians: a systematic review and meta-analysis

2014 John Wiley & Sons Ltd ;2014 John Wiley & Sons Ltd. ;ISSN: 1462-8902 ;EISSN: 1463-1326 ;DOI: 10.1111/dom.12293 ;PMID: 24655583 ;CODEN: DOMEF6

Searching Remote Databases, Please Wait